#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Paget's disease of the vulva Langerhans cell sarcoma Carcinoid syndrome Metastatic gastric cancer Medulloblastoma Langerhans' cell histiocytosis Rhabdomyosarcoma Gestational trophoblastic tumour Cutaneous lupus erythematosus Cardiac arrest Li-Fraumeni syndrome Transient ischaemic attack Neovascular age-related macular degeneration Pericarditis Neuroendocrine carcinoma More trials…

    Learn about Rare Diseases

    Pyogenic sterile arthritis pyoderma gangrenosum and acne syndrome – Basic Information Waldenstrom’s macroglobulinaemia – Treatment Prolymphocytic leukaemia – Trials in Disease Prolymphocytic leukaemia – Treatment Osteosarcoma – Diagnostics Lymphangiosarcoma – Trials in Disease Isodicentric chromosome 15 syndrome – Life with Disease Hairy cell leukaemia – Trials in Disease Progressive supranuclear palsy – Basic Information Encephalitis autoimmune – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Indocyanine Green Dipyridamole Indometacin Ph. Eur. ZINC GLUCONATE Sodium Iodide (123 I) Avalglucosidase Alfa Ascorbic Acid Ro7589655 Felzartamab Linvoseltamab Nintedanib Thiamine Amlitelimab Gskvx000000008866 Paclitaxel SGN-ALPV Ag-946 Adrc001 ZOREVUNERSEN SODIUM Potassium Iodide More therapies…

    Learn about Your Condition

    Testicular germ cell cancer Intestinal infarction Prolymphocytic leukaemia Infant sedation Primary biliary cholangitis Nasopharyngeal cancer Cortical dysplasia Triple positive breast cancer Hip arthroplasty Bronchiectasis Athetosis Aortic valve disease Somatic symptom disorder Ovarian cancer metastatic Pharyngeal cancer stage II More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Axon Clinical s.r.o.

Axon Clinical s.r.o.

Ostrovskeho 253/3, Smichov, Prague, 150 00, Czechia

Want to learn more about this study or check if you can participate? Contact us.

  • Study on the Effectiveness and Safety of EYE103 Compared to Ranibizumab for Patients with Diabetic Macular Edema

    Not recruiting

    4 1 1 1
    Investigated Diseases:
    • Diabetic retinal oedema
    Investigated Drugs:
    • Eye103
    • Fluorescein Sodium
    • Ranibizumab
    Austria Croatia Czechia France Germany Hungary +6

  • Study Comparing EYP-1901 and Aflibercept for Patients with Wet Age-Related Macular Degeneration

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Neovascular age-related macular degeneration
    Investigated Drugs:
    • VOROLANIB
    • Aflibercept
    Czechia Germany Hungary Poland Slovakia

  • Study of CVN424 for Reducing Motor Complications in Parkinson’s Disease Patients

    Not recruiting

    2 1
    Investigated Drugs:
    • 1-[2-[4-(2,4-DIFLUOROPHENOXY)PIPERIDIN-1-YL]-3-[[(3R)-OXOLAN-3-YL]AMINO]-7,8-DIHYDRO-5H-PYRIDO[3,4-B]PYRAZIN-6-YL]ETHANONE
    Czechia France Italy Poland Spain

  • Study on the Effectiveness and Safety of ANX007 Injections for Patients with Geographic Atrophy from Age-Related Macular Degeneration

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Dry age-related macular degeneration
    Investigated Drugs:
    • ANX007
    Austria Czechia France Germany Hungary Italy +3

  • Study on the Effects of AT-007 for Patients Aged 16-55 with Sorbitol Dehydrogenase Deficiency

    Not recruiting

    4 1
    Investigated Diseases:
    • Neuropathy peripheral
    Investigated Drugs:
    • GOVORESTAT
    Czechia Italy

  • Study on Risankizumab for Patients with Moderate to Severe Crohn’s Disease

    Not recruiting

    3 1
    Investigated Drugs:
    • Risankizumab
    Czechia Hungary Lithuania Poland

  • Study on the Effects of Zasocitinib for Patients with Moderate to Severe Ulcerative Colitis

    Not recruiting

    2 1
    Investigated Drugs:
    • Zasocitinib
    Belgium Bulgaria Czechia Denmark France Germany +7

  • Study on Lu AG09222 for Preventing Migraines in Adults Unresponsive to Previous Treatments

    Not recruiting

    2 1
    Investigated Diseases:
    • Migraine
    Investigated Drugs:
    • Lu Ag09222
    Bulgaria Czechia Denmark France Germany Hungary +5

  • Study on Aflibercept for Adults with Diabetic Macular Edema or Wet Age-Related Macular Degeneration

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Diabetic retinal oedema
    • Neovascular age-related macular degeneration
    Investigated Drugs:
    • Aflibercept
    Czechia Hungary Slovakia

  • Study of OPT-302 and Aflibercept for Patients with Wet Age-related Macular Degeneration

    Not recruiting

    3 1 1
    Investigated Diseases:
    • Neovascular age-related macular degeneration
    Investigated Drugs:
    • Vascular Endothelial Growth Factor Receptor 3 Extracellular Domains 1-3 Fused To A Igg1 Fc Fragment
    • Aflibercept
    Austria Bulgaria Croatia Czechia Estonia France +10
Previous Page
1 2 3 4 5
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!